Kornimate/medical-research-clean huggingface dataset:
diagnosis of depressive disorder malinger using the niacin skin response test (nsrt)

Conditions: Depressive Disorder; Malingering

Summary: this study will explore the specific response characteristics of the niacin skin response test in the population with depressive disorder malinger. the investigators expect that depressive disorder malinger can be discriminated by the niacin skin reaction test.

depressive disorder malingers are prevalent, and it is difficult to recognize. as an objective and scientific endophenotype of depressive disorders, the blunted features in nsrt are determined by genetic factors and are not influenced by the mental state of individual subjects at a particular moment, which can provide a reliable retrospective biological index for the determination of mental and psychological state of depressive disorder malinger. this study will explore the specific response characteristics of the niacin skin response test in the population with depressive disorder malinger, explore the application prospects of this technology in the field of biological identification, and establish a high-specificity biological diagnostic model for depressive disorder malinger and validate and optimize it, so as to provide a biological basis for the accurate and efficient identification of depressive disorder malingers using objective indexes in the process of clinical practice.

Eligibility criteria:
inclusion criteria: depressive disorder malinger group: 1. clinical complaints meeting dsm-5 criteria for the diagnosis of depressive disorder; 2. patients with first-episode fraudulent disease who meet the dsm-5 criteria for the diagnosis of z76.5; 3. age 18-60 years, males; 4. voluntary informed consent. depressive disorder group: 1. patients with a first depressive disorder meeting dsm-5 criteria; 2. age 18-60 years, males; 3. voluntary informed consent. healthy control group: 1. m.i.n.i scale rating without any mental disorder; 2. phq-9 \<5 ; 3. no history of mental illness, no family genetic history; 4. age 18-60 years old, males; 5. voluntary informed consent form. exclusion criteria: 1. history of traumatic brain injury; 2. continuous use of non-steroidal anti-inflammatory drugs within the last two weeks.
the effect of an urban sanitation intervention on child health

Conditions: Diarrhea; Helminthiasis

Summary: the purpose of this study is to determine the health impact of a basic sanitation intervention in maputo, mozambique.

we have designed a controlled, before-and-after (cba) effectiveness study to estimate the health impacts of an urban sanitation intervention in informal neighborhoods of maputo, mozambique, including an assessment of whether exposures and health outcomes vary by localized population density. the intervention consists of private pour-flush latrines (to septic tank) shared by multiple households in compounds or household clusters. we will measure objective health outcomes in approximately 1000 children (500 children with household access to interventions, 500 controls using existing shared private latrines in poor sanitary conditions), at two time points: immediately before the intervention and at follow-up after 12 months. the primary outcome is combined prevalence of enteric infections among children under 5 years of age. secondary outcome measures include soil transmitted helminth (sth) re-infection in children following baseline de-worming and prevalence of reported gastrointestinal illness. we will use exposure assessment, fecal source tracking, and microbial transmission modeling to examine whether and how routes of exposure for diarrheagenic pathogens and sths vary and transmission impacts of the pathogens following introduction of effective sanitation. our analysis will focus specifically on the impact of localized population density as a potential modifier of sanitation-related exposures.

Eligibility criteria:
inclusion criteria: * children normally resident in households with access to new shared sanitation (the intervention) as selected by implementing organisation (wsup) or control children normally resident in households sharing existing shared sanitation within geographically delimited project bounds and meeting wsup site selection criteria (including number of people served) exclusion criteria: * refusal to participate
effect of kangaroo baby massage on mother-infant interaction at home

Conditions: Premature; Low Birth Weight; Mother-Infant Interaction; Gain, Weight; Depression, Post-Partum; Breastfeeding; Feeding, Breast

Summary: the objective of this randomized clinical trial will determine the effectiveness of nursing intervention (kangaroo baby massage) on the interaction between mothers and premature, low birth weight infants at home the dyad mother- infant of the control group will receive kangaroo position kp and the dyad mother- infant mothers of the intervention group will receive the kangaroo baby massage kbm

participants and methods: 68 dyads mother-infant will randomize, 34 in intervention kbm group and 34 in control group kp, previous they meet inclusion criteria and accept their participation through informed consent. weight gain and kangaroo position days at home will be the primaries outcomes. the alert states, types of bc feeding, perceived maternal parental self-efficacy and postnatal depression. will be secondary outcomes. barnard's mother-child interaction theory supports the study

Eligibility criteria:
inclusion criteria * prematures and low birth weight infants in kangaroo position with a chronological age less than 3 months * the mothers take care the infant at home * baby with a weight equal to or greater than 1800 grams at the time of entry to the study. * baby whose birth was institutional or extra-institutional. * mothers with training in the kangaroo mother program * children controlled in the ambulatory kangaroo mother program exclusion criteria * children diagnosed with intraventricular hemorrhages grade iii and iv or congenital malformations * children who have more than one ambulatory kangaroo control * children who have been at home for more than 3 days without starting the ambulatory kangaroo control * babies with infections and other pathologies that require hospitalization during the study * presence of infectious diseases and other pathologies in the mother that require hospitalization * mother confirmed with positive test for covid 19 at the moment of the randomization * mothers with cognitive problems or mental disorders.

Keywords: massage kangaroo mother care low birth weight infant premature infant mother- infant interaction domiciliary nursing home health nursing telenursing
anfibatide phase 1 clinical trial in healthy volunteers

Conditions: Coronary Heart Disease; Coagulation Disorder

Summary: in this 94 healthy subjects phase i clinical trial, we assess the clinical profile of anfibatide, a specific glycoprotein ib antagonist. this study represents the first clinical evidence that anfibatide exhibits strong anti-platelet effects, excellent reversibility, and low bleeding potential in healthy human subjects.


Eligibility criteria:
inclusion criteria: * 1) healthy volunteers, aged 18-28 years, male and female were included, age difference less than 10 years; * 2) body weight: with body mass index (bmi) between 19-24, difference less than 10kg in the same group, bmi=body weight(kg)/height2; * 3) past medical history: no history of heart, liver, kidney, digestive tract, nervous system and metabolic disorder, or ulcer, significant hemorrhage, without the history of drug allergy and postural hypotension; * 4) medical examinations: with normal results in overall examinations (including heart rate, blood pressure, auscultation of heart and lung, palpation of liver and spleen, hepatic and renal function, hematology, coagulation function, urine analysis, stool analysis and occult blood test, electrocardiogram); * 5) have not received any medications within 2 weeks before the study; * 6) willing to participate in the study and give a signed informed consent form after understanding the study procedures and potential adverse reactions of the study product. exclusion criteria: * 1) history of hbv or hcv infection; * 2) addicted to smoking or alcohol; * 3) women during pregnancy, lactation or menstrual period; * 4) past history of hemoptysis, bloody stool, bleeding spots in the skin and mucous membrane, or hemorrhagic tendency (find themselves prone to bleeding in gums, nose, skin and mucous membrane, or hemoptysis); * 5) history of active bleeding (such as peptic ulcer, hemorrhoids, active tuberculosis, subacute bacterial endocarditis, etc); * 6) blood platelet count less than 150×109; * 7) trauma history (e.g., craniocerebral trauma) recently; * 8) past history of unexplained syncope or convulsion; * 9) history of organic or psychogenic disease or the disabled; * 10) persons who were unlikely to participate in the study (such as the infirm) in the investigator's opinion; * 11) have donated blood or experienced blood collection in other trials within 3 months.
a controlled trial of high dietary fiber intake on serum lipids

Conditions: Hyperlipidemia

Summary: the study evaluates high fiber diet intake in patients with hyperlipidemia.

dietary fiber intake has been shown to have modest effect in lowering cholesterol. however, most of these studies were done with 20g/daily fiber intake. not much is known about high dietary fiber intake (30-40 g/day) and serum cholesterol. also, there have been small studies that have shown modest decrease in oxidative stress by increasing dietary fiber intake. the goal of our study is to determine the efficacy /safety of high dietary fiber intake in raising hdl, lowering ldl, and lowering oxidative stress in patients with hyperlipidemia.

Eligibility criteria:
inclusion criteria: * all primary and secondary prevention patients aged 18 to 80 years with known or newly diagnosed isolated hypercholesteremia or combined hyperlipidemia. * inclusion criteria include patients with hdl \< 35 mg/dl for a man or \< 45mg/dl for women irrespective of ldl level. exclusion criteria: * any patients with unstable angina, untreated hypothyroidism, uncontrolled diabetes, other endocrine or metabolic diseases not actively treated, acute inflammatory diseases, severe gastrointestinal diseases, chronic renal insufficiency (gfr\<30), end stage renal disease, liver disease or other severe diseases such as cancer, triglyceride level greater than 600 mg/dl, pregnant females, chronic use of systemic corticosteroid, or anticoagulants. * patients who were recently started or recently had their lipid lowering medications changed within the last 4 weeks will be excluded.

Keywords: low hdl
role of leukotriene receptor antagonists in treatment of chronic periodontitis

Conditions: Chronic Periodontitis

Summary: the adjunctive use of leukotriene receptor antagonist (montelukast) along with scaling and root planing in patients with chronic periodontitis leads to host inflammatory response modulation and decrease in serum c reactive protein (crp) levels. if proven this will open new vistas in treatment of chronic periodontitis.

a rct was carried out to check the efficacy of montelukast as an adjunct to scaling and root planing. the patients were randomised to either test group (srp + montelukast) and control group (srp). clinical parameters were assessed at baseline, 3 weeks and 6 weeks. serum c-reactive protein levels were assessed at baseline, 3 weeks and 6 weeks.

Eligibility criteria:
inclusion criteria: 1. patients within age group of 30 to 55 years. 2. systemically healthy individuals. 3. patients with chronic generalized periodontitis (moderate and severe) according to center of disease control (cdc) working group, 2007 criteria exclusion criteria: 1. patients with systemic illnesses (i.e., diabetes mellitus, cancer, human immunodeficiency syndrome, bone metabolic diseases, or disorders that compromise wound healing, radiation, or immunosuppressive therapy), 2. smoking, 3. chronic alcoholics, 4. pregnancy or lactation, 5. use of non-steroidal anti-inflammatory drugs (nsaids), steroids or antibiotics / antimicrobials within january 2012 to jun 2013, 6. confirmed or suspected intolerance to montelukast, 7. periodontal therapy done within the january 2012 to jun 2013.

Keywords: leukotriene receptor antagonist chronic periodontitis scaling and root planing c- reactive protein
lactobacillus rhamnosus gg in the middle ear and adenoid tonsil

Conditions: Upper Respiratory Infection; Acute Otitis Media

Summary: the purpose of this study is to evaluate the effect of oral administration of probiotic lactobacillus rhamnosus gg in middle ear and adenoid tonsil.


Eligibility criteria:
inclusion criteria: * recurrent otitis media * secretory otitis media * chronic rhinitis * recurrent sinusitis exclusion criteria: * significant illness
effects of intraoperative dexamethasone and ondansetron on postoperative nausea and vomiting in microvascular decompression surgery

Conditions: Microvascular Decompression Surgery; Postoperative Nausea and Vomiting

Summary: postoperative nausea and vomiting (ponv) is a common problem and may lead to catastrophic complications, especially in neurosurgical cases. the aim of this study was to evaluate the effects of dexamethasone and ondansetron for preventing ponv in patients who underwent microvascular decompression surgery (mvd).

a prospective, double-blinded randomized control trial was conducted with 54 patients who underwent mvd. patients were allocated into two groups. the study group (gr. d) received intraoperative dexamethasone 4 mg iv and ondansetron 4 mg iv, whereas the control group (gr. n) received placebo (0.9% normal saline 1 ml iv and 0.9% normal saline 2 ml iv). the incidence and severity of ponv were observed at 1, 2, 4 and 24 hr post-surgery.

Eligibility criteria:
inclusion criteria: * patients who were scheduled for mvd of trigeminal nerve root * patients who had a physical status classification of i to iii according to the american society of anesthesiologists, and those who had a body mass index of 18 to 35 kg/m2 exclusion criteria: * patients on long-term administration of dexamethasone or ondansetron, those with a history of allergic reactions to dexamethasone or ondansetron, those who had undergone antiemetic therapy within 24 hr before surgery, those with underlying liver or renal failure, those who were pregnant, or those who had undergone emergency surgery.
the effect of intraabdominal saline irrigation in abdominal hysterectomies

Conditions: Gynecologic Surgery

Summary: the objective of this prospective randomised clinic study is to investigate the effect of peritoneal cavity saline irrigation during abdominal hysterectomies on postoperative infectious morbidities and gastrointestinal disturbance. the participants will be randomised to either an irrigation of abdominal cavity or the control group after vaginal closure. assignment to one of the two treatment groups will be determined using a computer generated random numbers. primary outcome is the rate of postoperative infectious morbidities. secondary outcome is the rate of gastrointestinal disturbances (nausea, vomiting), use of antiemetic drugs and pain score in the postoperative period. 100 patients in each treatment arm planned.


Eligibility criteria:
inclusion criteria: * patients undergoing hysterectomies for benign causes exclusion criteria: * patients who have diabetes mellitus patients undergoing hysterectomy for pelvic inflammatory disease or tuboovarian abscess

Keywords: saline irrigation abdominal hysterectomy postoperative infectious morbidities gastrointestinal disturbances
aza+lus vs aza monotherapy in hr-mds

Conditions: Higher-risk Myelodysplastic Syndrome

Summary: this study is a randomized, prospective, single-center, open-label cohort study involving untreated hr-mds patients. the patients were divided randomized into aza+lus cohort and aza monotherapy cohort.

the hypomethylating agents (hma) azacitidine (aza) and decitabine (dec) have been shown to improve survival and delay disease progression in patients with high-risk mds. they are recommended by the nccn as first-line treatments for patients with high-risk mds. clinical trials have demonstrated an or rate of approximately 40-50% with aza in patients with high-risk mds. despite the efficacy of hma therapy, the rate of transfusion independence remains low. anemia remains the most prominent symptom in refractory patients, with very limited options for subsequent treatment. prolonged anemia affects every organ function and seriously affects the prognosis of patients. luspatercept is currently approved for the treatment of patients with both erythropoiesis receptor agonist ( esa) treatment failures in transfusion-dependent low-risk mds-rs patients. in a randomized controlled phase iii clinical trial, compared to a placebo group, luspatercept significantly improved transfusion dependence and improved hemoglobin and quality of life in refractory mds-rs patients. a recent conference report suggested that there was no significant difference in efficacy between low-risk and high-risk patients treated with luspatercept and that the hi rate for high-risk patients treated with luspatercept monotherapy was approximately 50%. thus this study aimed to compare the efficacy of aza+luspatercept and aza monotherapy.

Eligibility criteria:
inclusion criteria: * age ≥18 years old * diagnosed as higher-risk mds (ipss intermediate-2/high-risk, or ipss-r \>3.5, or ipss-m moderate high-, high-, very high-risk) * untreated patients * liver and kidney function less than 2 times of upper limit of normal * ecog≤2 and expected survival more than 6 months * informed consent signed exclusion criteria: * with active infection * other malignant tumors * obvious abnormal liver and kidney function, or abnormal function of other organs * combined with myelofibrosis * have undergone bone marrow transplantation * pregnant or lactating women, or men who have recent reproductive needs * allergic to azacytidine, rotercept or excipients * history of polysorbate 80 allergy * refuse to sign informed consent * researchers consider it inappropriate to participate in the experiment

Keywords: luspatercept azacitidine higher-risk myelodysplastic syndrome
synovial fluid biomarkers pre and post hymovis knee injection

Conditions: Knee Osteoarthritis

Summary: this njh investigator initiated study funded by fidia will prospectively perform 2 ultrasound (us) guided knee aspirations in patients with knee osteoarthritis using a pneumatic compressive device (kneetap ™) at baseline and at 3 months following 2 hymovis® injections. synovial fluid catabolic and anabolic proteins will be compared to those values in the peripheral blood and correlated with clinical outcome measurements at 3 ,6 and 12 months compared to baseline values; womac, sf 36, visual analog pain scale, 6 minute walking distance and sf volumes quantitated by us.

50 subjects between 21-80 years with a bmi \ 0.5 ml of synovial fluid is obtained they will received the first of 2 fda approved hymovis knee injections. a second ultrasound guided hymovis intra-synovial space injection will be administered in one week with a repeat arthrocentesis in 3 months. subjects will be compensated $ 50 for each of 4 of 5 study visits. clinical outcome measures at study visits 1, 3 (3 months) 4 at (6 months) and 5 (12 months will include: vas (visual analog global pain (1-10), sf -36 ,womac questionnaires (western ontario and mcmaster university arthritis index pain scale), measured distance on 6 minute walking distance test and synovial fluid depth measured by ultrasound. the synovial fluid biomarker panel will include values of over 45 separate cytokines,.chemokines and proteins from subjects pre vs post hymovis injections and compared to values in the peripheral blood obtained simultaneously. sf biomarker analysis will be performed on cryopreserved samples using fluorescence multiplex bead based assays (luminex) or by elisa. all values as well as clinical outcome parameters will be entered into the redcap system for statistical analysis

Eligibility criteria:
inclusion criteria: * mild to moderate knee osteoarthritis on x ray * age 21-80 exclusion criteria * pregnant * bmi \> 40 * history of systemic immune disorders * knee arthroplasty with replacement * knee infection or surgery within 1 year * glucocorticoid injection within 3 months inability to ambulate for 6 minutes without walking assistive devices * unable to provide informed consent * patients with a clinical contra-indication for an arthrocentesis or adverse reaction to prior intra-articular lidocaine or ha injections.
treatment of pseudovitellium detachment with open-label anecortave acetate sterile suspension (15 mg)

Conditions: Pseudovitellium Detachment; Eye Diseases

Summary: the purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control pseudovitelliform detachment.


Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of patients with pseudovitellium detachment. 2. patients must be at least 18 years of age. 3. visual acuity of 20/30 to 20/320 in study eye on the early treatment of diabetic retinopathy study (etdrs) visual acuity chart 4. visual acuity of 20/800 or better in fellow eye on the etdrs visual acuity chart exclusion criteria: 1. patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions. 2. patients who have undergone intraocular surgery within the last 2 months. 3. patient participating in any other investigational drug study. 4. use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication. 5. inability to obtain photographs to document choroidal neovascularization (cnv) (including difficulty with venous access). 6. patient with significant liver disease or uremia. 7. patient with known adverse reaction to fluorescein and indocyanine green or iodine. 8. patient has a history of any medical condition which would preclude scheduled visits or completion of study 9. patient has had insertion of scleral buckle in the study eye 10. patient has received radiation treatment 11. patient is on anticoagulant therapy with the exception of aspirin 12. patient is pregnant or nursing.
prenatal yoga for pregnancy related back pain

Conditions: Pregnancy Related

Summary: this is a pilot feasibility study investigating prenatal yoga for pregnancy related back pain.


Eligibility criteria:
inclusion criteria: * uncomplicated pregnancies starting at 12-26 weeks of gestation * pregnant women with and without back pain who had no regular yoga practice. exclusion criteria: * significant back pathology * pregnancy complications * non-english speaking * otherwise were not able to participate (eg. transportation, scheduling issues)